RNLXD (Renalytix) Common Stock: $1.40 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNLXD Renalytix PLC RNLXD
46 GF Score
Price $4.11
GF Value $7.34
! 3 Warning Signs
View Full Analysis

What is Renalytix Common Stock?

Renalytix RNLXD +0.46% 46 Common Stock is $1.40 Mil as of Dec. 2025. GuruFocus rates RNLXD with a GF Score™ of 46/100 and a GF Value™ of $7.34. The stock has 3 warning signs investors should review.

Renalytix's quarterly common stock increased from Dec. 2024 ($1.06 Mil) to Jun. 2025 ($1.10 Mil) and increased from Jun. 2025 ($1.10 Mil) to Dec. 2025 ($1.40 Mil).

Renalytix's annual common stock increased from Jun. 2023 ($0.29 Mil) to Jun. 2024 ($0.50 Mil) and increased from Jun. 2024 ($0.50 Mil) to Jun. 2025 ($1.10 Mil).

Renalytix Common Stock Historical Data

* Premium members only.

The historical data trend for Renalytix's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix Common Stock Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial 0.23 0.23 0.29 0.50 1.10

Renalytix Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.50 1.06 1.10 1.40
RNLXD
46GF Score
Renalytix PLC RNLXD
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renalytix Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $1.40 Mil mean?
Renalytix (RNLXD) has a Common Stock of $1.40 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Renalytix and its competitors.
Is Renalytix's Common Stock too high?
Renalytix's current Common Stock is $1.40 Mil. Overall, Renalytix has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Renalytix's Common Stock compare to VEEV and BTSG?
Renalytix's Common Stock of $1.40 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Healthcare Providers & Services company?
A good Common Stock depends on the Healthcare Providers & Services industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Renalytix and its competitors. Renalytix's current Common Stock is $1.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Renalytix (RNLXD) has a current Common Stock of $1.40 Mil. The stock's GF Value™ is $7.34, compared to a current price of $4.11 — trading 44% below its estimated fair value. The current Common Stock is $1.40 Mil. Renalytix's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Renalytix (RNLXD), the current Common Stock is $1.40 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renalytix (RNLXD) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be undervalued. The current stock price of $4.11 is trading 44% below its estimated GF Value™ of $7.34.

Key valuation signals for RNLXD:

  • Common Stock: $1.40 Mil
  • GF Value™: $7.34 vs. price of $4.11 (44% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the RNLXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
46GF Score

Get the complete analysis for RNLXD

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$7.34
GF Value